Compare Cytokinetics Inc (CYTK) vs iShares MSCI Hong Kong ETF (EWH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares MSCI Hong Kong ETF — how do they compare? Cytokinetics Inc trades at $62.91 (market cap $8.62B), while iShares MSCI Hong Kong ETF trades at $22.06 (market cap $1.16B). The key difference: Cytokinetics Inc is far larger — about 7.4× iShares MSCI Hong Kong ETF's market cap, and iShares MSCI Hong Kong ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and iShares MSCI Hong Kong ETF for 61 Days on average.
| CYTK | EWH | |
|---|---|---|
Market Cap | $8.62B | $1.16B |
Volume | 2,594,626 | 3,176,523 |
Sector | Health | Broad Market / Factor |
52-Week High | $87.26 | $24.55 |
52-Week Low | $54.76 | $20.66 |
Typical Hold Time | 19 Days | 61 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $62.01, up 1.46% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported Q2 2026 EPS of -$1.50, beating expectations, but maintains deeply negative profitability with a net income margin of -1,321.12% for 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy studies and presentations at major medical conferences.
Wall Street sentiment is overwhelmingly bullish with a 97.14% buy rating and a $112.60 consensus price target, signaling strong upside potential. However, high cash burn, substantial losses, and significant debt-to-asset ratio of 81.23% present substantial financial risks. Investment appeal hinges on successful commercialization of its pipeline amid intense competition.
EWH, the iShares MSCI Hong Kong ETF, trades at $21.72 with a 0.65% daily gain amid bearish technical signals. The ETF faces headwinds from Hong Kong's Hang Seng Index decline, down over 11% from yearly highs due to Federal Reserve policy and US-Iran tensions. Moving averages signal strong bearish momentum while oscillators remain neutral. Recent institutional selling includes Empowered Funds LLC reducing its position by 70.2% in Q2 2026.
Outlook remains cautious given Hong Kong market volatility and geopolitical risks. The ETF's performance is tied to Chinese tech stocks and regional economic conditions. Near-term resistance at $22 presents a key level for bullish reversal, but continued pressure on Asian markets suggests limited upside potential without significant catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares MSCI Hong Kong ETF
EWH tracks the MSCI Hong Kong 25/50 Index, providing broad exposure to large and mid-cap companies listed in Hong Kong. It focuses on the established pillars of the local economy, with heavy weightings in financials, real estate, and utilities, serving as a single-country diversification tool.
Read more on EWH →
